{"id":317566,"date":"2026-10-21T09:08:22","date_gmt":"2026-10-21T03:38:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=317566"},"modified":"2026-10-21T09:08:22","modified_gmt":"2026-10-21T03:38:22","slug":"ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/","title":{"rendered":"Ambalal Sarabhai vs Sanjivani Paranteral vs Themis Medicare: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ambalal Sarabhai Enterprises PE 23.29, mkt cap Rs 316 crore. Sanjivani Paranteral PE 29.84, mkt cap Rs 223 crore. Themis Medicare PE 25.17, mkt cap Rs 1,006 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Ambalal Sarabhai Enterprises carries a market capitalisation of about Rs 316 crore, against Rs 223 crore for Sanjivani Paranteral and Rs 1,006 crore for Themis Medicare, with return on equity of 11.24%, 13.87% and 0.42% respectively. Each company&#8217;s numbers are presented here without a declared preference, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare_Company_Overview\" title=\"Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare: Company Overview\">Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare_Valuation_and_Profitability_Snapshot\" title=\"Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Valuation and Profitability Snapshot\">Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare_Latest_Quarterly_Results\" title=\"Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Latest Quarterly Results\">Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare_Five-Quarter_Revenue_and_Net_Profit_Trend\" title=\"Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend\">Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#FAQs_on_Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare\" title=\"FAQs on Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare\">FAQs on Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#What_is_the_market_cap_difference_between_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\" title=\"What is the market cap difference between Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\">What is the market cap difference between Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#What_are_the_PE_and_PB_ratios_of_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\" title=\"What are the PE and PB ratios of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\">What are the PE and PB ratios of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#What_is_the_debt_to_equity_ratio_for_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\" title=\"What is the debt to equity ratio for Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\">What is the debt to equity ratio for Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#What_were_the_latest_quarterly_revenue_and_net_profit_of_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\" title=\"What were the latest quarterly revenue and net profit of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\">What were the latest quarterly revenue and net profit of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare\/#Does_this_comparison_recommend_one_of_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\" title=\"Does this comparison recommend one of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\">Does this comparison recommend one of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare_Company_Overview\"><\/span><strong>Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Ambalal Sarabhai Enterprises<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 316 crore, a return on equity of 11.24% and a book value of Rs 20.66 per share. Its quarterly revenue moved from Rs 48.70 crore in June 2025 to Rs 45.59 crore in June 2026, a change of -6.4%.<\/p>\n<p><strong>Sanjivani Paranteral<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 223 crore, a return on equity of 13.87% and a book value of Rs 39.28 per share. Its quarterly revenue moved from Rs 17.93 crore in June 2025 to Rs 23.99 crore in June 2026, a change of +33.8%.<\/p>\n<p><strong>Themis Medicare<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,006 crore, a return on equity of 0.42% and a book value of Rs 39.74 per share. Its quarterly revenue moved from Rs 98.76 crore in June 2025 to Rs 87.95 crore in June 2026, a change of -10.9%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare_Valuation_and_Profitability_Snapshot\"><\/span><strong>Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/ambalalsa\/ambalal-sarabhai-enterprises-ltd-share-price-today\">Ambalal Sarabhai Enterprises<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/sanjivin\/sanjivani-paranteral-ltd-share-price-today\">Sanjivani Paranteral<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/themismed\/themis-medicare-ltd-share-price-today\">Themis Medicare<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 316 crore<\/td>\n<td>Rs 223 crore<\/td>\n<td>Rs 1,006 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>23.29<\/td>\n<td>29.84<\/td>\n<td>25.17<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>2.00<\/td>\n<td>4.61<\/td>\n<td>2.75<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>11.24%<\/td>\n<td>13.87%<\/td>\n<td>0.42%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>1.77<\/td>\n<td>6.07<\/td>\n<td>4.34<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<td>0.00%<\/td>\n<td>0.46%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.36<\/td>\n<td>0.30<\/td>\n<td>0.25<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>20.66<\/td>\n<td>39.28<\/td>\n<td>39.74<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Ambalal Sarabhai Enterprises trades at a PE of 23.29 and a PB of 2.00, Sanjivani Paranteral at a PE of 29.84 and a PB of 4.61, while Themis Medicare trades at a PE of 25.17 and a PB of 2.75. On return on equity, the three post 11.24%, 13.87% and 0.42% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.46%. Themis Medicare has the highest market capitalisation of the three at Rs 1,006 crore, while Sanjivani Paranteral has the lowest at Rs 223 crore. Sanjivani Paranteral has the highest PE ratio of the three at 29.84, while Ambalal Sarabhai Enterprises has the lowest at 23.29. Sanjivani Paranteral has the highest return on equity of the three at 13.87%, while Themis Medicare has the lowest at 0.42%. Ambalal Sarabhai Enterprises has the highest debt to equity ratio of the three at 0.36, while Themis Medicare has the lowest at 0.25. Debt to equity is 0.36, 0.30 and 0.25 for the three respectively.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare_Latest_Quarterly_Results\"><\/span><strong>Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<th>YoY Change (Net Profit)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ambalal Sarabhai Enterprises<\/td>\n<td>Rs 45.59 crore<\/td>\n<td>Rs 3.98 crore<\/td>\n<td>-6.4%<\/td>\n<td>-33.1%<\/td>\n<td>-51.6%<\/td>\n<\/tr>\n<tr>\n<td>Sanjivani Paranteral<\/td>\n<td>Rs 23.99 crore<\/td>\n<td>Rs 2.49 crore<\/td>\n<td>+33.8%<\/td>\n<td>+73.7%<\/td>\n<td>+43.9%<\/td>\n<\/tr>\n<tr>\n<td>Themis Medicare<\/td>\n<td>Rs 87.95 crore<\/td>\n<td>Rs 24.61 crore<\/td>\n<td>-10.9%<\/td>\n<td>+9.7%<\/td>\n<td>NA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare_Five-Quarter_Revenue_and_Net_Profit_Trend\"><\/span><strong>Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare, which helps separate a one-quarter move from a steadier pattern.<\/p>\n<p><strong>Quarterly revenue (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Ambalal Sarabhai Enterprises<\/th>\n<th>Sanjivani Paranteral<\/th>\n<th>Themis Medicare<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 48.70 crore<\/td>\n<td>Rs 17.93 crore<\/td>\n<td>Rs 98.76 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 46.07 crore<\/td>\n<td>Rs 15.66 crore<\/td>\n<td>Rs 81.23 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 54.58 crore<\/td>\n<td>Rs 22.36 crore<\/td>\n<td>Rs 91.41 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 68.10 crore<\/td>\n<td>Rs 13.81 crore<\/td>\n<td>Rs 80.20 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 45.59 crore<\/td>\n<td>Rs 23.99 crore<\/td>\n<td>Rs 87.95 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Quarterly net profit (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Ambalal Sarabhai Enterprises<\/th>\n<th>Sanjivani Paranteral<\/th>\n<th>Themis Medicare<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 8.22 crore<\/td>\n<td>Rs 1.73 crore<\/td>\n<td>-Rs 14.22 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>-Rs 0.56 crore<\/td>\n<td>Rs 1.64 crore<\/td>\n<td>-Rs 3.62 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 3.64 crore<\/td>\n<td>Rs 2.78 crore<\/td>\n<td>Rs 10.09 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 6.50 crore<\/td>\n<td>Rs 0.55 crore<\/td>\n<td>Rs 8.89 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 3.98 crore<\/td>\n<td>Rs 2.49 crore<\/td>\n<td>Rs 24.61 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Ambalal Sarabhai Enterprises reported revenue of Rs 48.70 crore in June 2025 and Rs 45.59 crore in June 2026, a change of -6.4% across the period. Its highest quarterly revenue in this window was Rs 68.10 crore in March 2026. Net profit stood at Rs 3.98 crore in June 2026, which is a net profit margin of 8.73%. Ambalal Sarabhai Enterprises reported a net loss in September 2025.<\/p>\n<p>Sanjivani Paranteral reported revenue of Rs 17.93 crore in June 2025 and Rs 23.99 crore in June 2026, a change of +33.8% across the period. Its highest quarterly revenue in this window was Rs 23.99 crore in June 2026. Net profit stood at Rs 2.49 crore in June 2026, which is a net profit margin of 10.38%.<\/p>\n<p>Themis Medicare reported revenue of Rs 98.76 crore in June 2025 and Rs 87.95 crore in June 2026, a change of -10.9% across the period. Its highest quarterly revenue in this window was Rs 98.76 crore in June 2025. Net profit stood at Rs 24.61 crore in June 2026, which is a net profit margin of 27.98%. Themis Medicare reported a net loss in June 2025 and September 2025.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, order flow, raw material costs and the small revenue base that makes quarterly results swing. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.<\/p>\n<p>It also helps to read the latest quarterly filings and investor presentations of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Ambalal_Sarabhai_Enterprises_vs_Sanjivani_Paranteral_vs_Themis_Medicare\"><\/span><strong>FAQs on Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\"><\/span><strong>What is the market cap difference between Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, Ambalal Sarabhai Enterprises has a market cap of approximately Rs 316 crore, Sanjivani Paranteral is at approximately Rs 223 crore, and Themis Medicare is at approximately Rs 1,006 crore. Themis Medicare is the largest of the three, and its market capitalisation is about 4.5 times that of Sanjivani Paranteral, the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_PE_and_PB_ratios_of_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\"><\/span><strong>What are the PE and PB ratios of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, the PE ratios stand at 23.29, 29.84 and 25.17 respectively, and the price to book ratios stand at 2.00, 4.61 and 2.75 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and healthcare and against each company&#8217;s own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare post ROE of 11.24%, 13.87% and 0.42% respectively as of October 2026. Sanjivani Paranteral has the highest return on equity of the three at 13.87%, while Themis Medicare has the lowest at 0.42%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare figures.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare carry dividend yields of 0.00%, 0.00% and 0.46% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\"><\/span><strong>What is the debt to equity ratio for Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ambalal Sarabhai Enterprises carries a debt to equity of 0.36, Sanjivani Paranteral of 0.30, and Themis Medicare of 0.25. Ambalal Sarabhai Enterprises has the highest debt to equity ratio of the three at 0.36, while Themis Medicare has the lowest at 0.25. The debt to equity ratio compares total borrowings with shareholders&#8217; funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and healthcare need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_latest_quarterly_revenue_and_net_profit_of_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\"><\/span><strong>What were the latest quarterly revenue and net profit of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For Q1 FY27 (quarter ended June 2026), Ambalal Sarabhai Enterprises reported revenue of Rs 45.59 crore and net profit of Rs 3.98 crore, Sanjivani Paranteral reported revenue of Rs 23.99 crore and net profit of Rs 2.49 crore, and Themis Medicare reported revenue of Rs 87.95 crore and net profit of Rs 24.61 crore. Compared with the quarter ended June 2025, revenue changed by -6.4% for Ambalal Sarabhai Enterprises, +33.8% for Sanjivani Paranteral and -10.9% for Themis Medicare. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_this_comparison_recommend_one_of_Ambalal_Sarabhai_Enterprises_Sanjivani_Paranteral_and_Themis_Medicare\"><\/span><strong>Does this comparison recommend one of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and healthcare, it also helps to look at factors such as regulatory approvals, order flow, raw material costs and the small revenue base that makes quarterly results swing. Reading the latest filings and investor presentations of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, Ambalal Sarabhai Enterprises has a market cap of approximately Rs 316 crore, Sanjivani Paranteral is at approximately Rs 223 crore, and Themis Medicare is at approximately Rs 1,006 crore. Themis Medicare is the largest of the three, and its market capitalisation is about 4.5 times that of Sanjivani Paranteral, the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the PE and PB ratios of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, the PE ratios stand at 23.29, 29.84 and 25.17 respectively, and the price to book ratios stand at 2.00, 4.61 and 2.75 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and healthcare and against each company's own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare post ROE of 11.24%, 13.87% and 0.42% respectively as of October 2026. Sanjivani Paranteral has the highest return on equity of the three at 13.87%, while Themis Medicare has the lowest at 0.42%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare figures.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare carry dividend yields of 0.00%, 0.00% and 0.46% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ambalal Sarabhai Enterprises carries a debt to equity of 0.36, Sanjivani Paranteral of 0.30, and Themis Medicare of 0.25. Ambalal Sarabhai Enterprises has the highest debt to equity ratio of the three at 0.36, while Themis Medicare has the lowest at 0.25. The debt to equity ratio compares total borrowings with shareholders' funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and healthcare need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare comparison.\"}},{\"@type\":\"Question\",\"name\":\"What were the latest quarterly revenue and net profit of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For Q1 FY27 (quarter ended June 2026), Ambalal Sarabhai Enterprises reported revenue of Rs 45.59 crore and net profit of Rs 3.98 crore, Sanjivani Paranteral reported revenue of Rs 23.99 crore and net profit of Rs 2.49 crore, and Themis Medicare reported revenue of Rs 87.95 crore and net profit of Rs 24.61 crore. Compared with the quarter ended June 2025, revenue changed by -6.4% for Ambalal Sarabhai Enterprises, +33.8% for Sanjivani Paranteral and -10.9% for Themis Medicare. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare results.\"}},{\"@type\":\"Question\",\"name\":\"Does this comparison recommend one of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and healthcare, it also helps to look at factors such as regulatory approvals, order flow, raw material costs and the small revenue base that makes quarterly results swing. Reading the latest filings and investor presentations of Ambalal Sarabhai Enterprises, Sanjivani Paranteral and Themis Medicare directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare compared on market cap, PE, ROE and quarterly results, as of October 2026.<\/p>\n","protected":false},"author":36,"featured_media":317565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[11016,1019],"class_list":["post-317566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-and-healthcare","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["317565"],"rank_math_title":["Ambalal Sarabhai vs Sanjivani Paranteral vs Themis Medicare"],"rank_math_description":["Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare compared on market cap, PE, ROE and quarterly results, as of October 2026."],"rank_math_focus_keyword":["Ambalal Sarabhai Enterprises vs Sanjivani Paranteral vs Themis Medicare"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/ambalal-sarabhai-vs-sanjivani-paranteral-vs-themis-medicare-which-stock-should.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/317566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=317566"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/317566\/revisions"}],"predecessor-version":[{"id":317567,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/317566\/revisions\/317567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/317565"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=317566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=317566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=317566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}